gene therapy gene therapy gene therapy is a medical field which focuses on the genetic modification of cells to produce a therapeutic effect or the treatment of disease by repairing or reconstructing defective genetic material. the first attempt at modifying human dna was performed in 1980, by martin cline, but the first successful nuclear gene transfer in humans, approved by the national institutes of health, was performed in may 1989. the first therapeutic use of gene transfer as well as the first direct insertion of human dna into the nuclear genome was performed by french anderson in a trial starting in september 1990. it is thought to be able to cure many genetic disorders or treat them over time. part of a series ongenetic engineering genetically modified organisms bacteria viruses animals mammals fish insects plants maize/corn rice soybean potato history and regulation history regulation substantial equivalence cartagena protocol on biosafety process techniques molecular cloning recombinant dna gene delivery transformation transfection transduction genome editing talen crispr applications genetically modified crops food gene therapy designer baby controversies genetically modified food controversies gmo conspiracy theories pusztai affair séralini affair starlink corn recall he jiankui affair between 1989 and december 2018, over 2,900 clinical trials were conducted, with more than half of them in phase i. in 2003, gendicine became the first gene therapy to receive regulatory approval. since that time, further gene therapy drugs were approved, such as glybera (2012), strimvelis (2016), kymriah (2017), luxturna (2017), onpattro (2018), zolgensma (2019), abecma (2021), adstiladrin, roctavian and hemgenix (all 2022). most of these approaches utilize adeno-associated viruses (aavs) and lentiviruses for performing gene insertions, in vivo and ex vivo, respectively. aavs are characterized by stabilizing the viral capsid, lower immunogenicity, ability to transduce both dividing and nondividing cells, the potential to integrate site specifically and to achieve long-term expression in the in-vivo treatment. aso / sirna approaches such as those conducted by alnylam and ionis pharmaceuticals require non-viral delivery systems, and utilize alternative mechanisms for trafficking to liver cells by way of galnac transporters. not all medical procedures that introduce alterations to a patient's genetic makeup can be considered gene therapy. bone marrow transplantation and organ transplants in general have been found to introduce foreign dna into patients. background gene therapy was conceptualized in 1972, by authors who urged caution before commencing human gene therapy studies. the first attempt, an unsuccessful one, at gene therapy (as well as the first case of medical transfer of foreign genes into humans not counting organ transplantation) was performed by martin cline on 10 july 1980. cline claimed that one of the genes in his patients was active six months later, though he never published this data or had it verified and even if he is correct, it's unlikely it produced any significant beneficial effects treating beta thalassemia. after extensive research on animals throughout the 1980s and a 1989 bacterial gene tagging trial on humans, the first gene therapy widely accepted as a success was demonstrated in a trial that started on 14 september 1990, when ashanthi desilva was treated for ada-scid. the first somatic treatment that produced a permanent genetic change was initiated in 1993. the goal was to cure malignant brain tumors by using recombinant dna to transfer a gene making the tumor cells sensitive to a drug that in turn would cause the tumor cells to die. the polymers are either translated into proteins, interfere with target gene expression, or possibly correct genetic mutations. the most common form uses dna that encodes a functional, therapeutic gene to replace a mutated gene. the polymer molecule is packaged within a "vector", which carries the molecule inside cells. early clinical failures led to dismissals of gene therapy. clinical successes since 2006 regained researchers' attention, although as of 2014, it was still largely an experimental technique. these include treatment of retinal diseases leber's congenital amaurosis and choroideremia, x-linked scid, ada-scid, adrenoleukodystrophy, chronic lymphocytic leukemia (cll), acute lymphocytic leukemia (all), multiple myeloma, haemophilia, and parkinson's disease. between 2013 and april 2014, us companies invested over $600 million in the field. the first commercial gene therapy, gendicine, was approved in china in 2003, for the treatment of certain cancers. in 2011, neovasculgen was registered in russia as the first-in-class gene-therapy drug for treatment of peripheral artery disease, including critical limb ischemia. in 2012, glybera, a treatment for a rare inherited disorder, lipoprotein lipase deficiency, became the first treatment to be approved for clinical use in either europe or the united states after its endorsement by the european commission. following early advances in genetic engineering of bacteria, cells, and small animals, scientists started considering how to apply it to medicine. two main approaches were considered – replacing or disrupting defective genes. scientists focused on diseases caused by single-gene defects, such as cystic fibrosis, haemophilia, muscular dystrophy, thalassemia, and sickle cell anemia. glybera treats one such disease, caused by a defect in lipoprotein lipase. dna must be administered, reach the damaged cells, enter the cell and either express or disrupt a protein. multiple delivery techniques have been explored. the initial approach incorporated dna into an engineered virus to deliver the dna into a chromosome. naked dna approaches have also been explored, especially in the context of vaccine development. generally, efforts focused on administering a gene that causes a needed protein to be expressed. more recently, increased understanding of nuclease function has led to more direct dna editing, using techniques such as zinc finger nucleases and crispr. the vector incorporates genes into chromosomes. the expressed nucleases then knock out and replace genes in the chromosome. as of 2014 these approaches involve removing cells from patients, editing a chromosome and returning the transformed cells to patients. gene editing is a potential approach to alter the human genome to treat genetic diseases, viral diseases, and cancer. as of 2020 these approaches are being studied in clinical trials. classification breadth of definition in 1986, a meeting at the institute of medicine defined gene therapy as the addition or replacement of a gene in a targeted cell type. in the same year, the fda announced that it had jurisdiction over approving "gene therapy" without defining the term. the fda added a very broad definition in 1993 of any treatment that would ‘modify or manipulate the expression of genetic material or to alter the biological properties of living cells’. in 2018 this was narrowed to ‘products that mediate their effects by transcription or translation of transferred genetic material or by specifically altering host (human) genetic sequences’. writing in 2018, in the journal of law and the biosciences, sherkow et al. argued for a narrower definition of gene therapy than the fda's in light of new technology that would consist of any treatment that intentionally and permanently modified a cell's genome, with the definition of genome including episomes outside the nucleus but excluding changes due to episomes that are lost over time. this definition would also exclude introducing cells that did not derive from a patient themselves, but include ex vivo approaches, and would not depend on the vector used. during the covid-19 pandemic, some academics insisted that the mrna vaccines for covid were not gene therapy to prevent the spread of incorrect information that the vaccine could alter dna, other academics maintained that the vaccines were a gene therapy because they introduced genetic material into a cell. fact-checkers, such as full fact, reuters, politifact, and factcheck.org said that calling the vaccines a gene therapy was incorrect. podcast host joe rogan was criticized for calling mrna vaccines gene therapy as was british politician andrew bridgen, with fact checker full fact calling for bridgen to be removed from the conservative party for this and other statements. genes present or added gene therapy encapsulates many forms of adding different nucleic acids to a cell. gene augmentation adds a new protein coding gene to a cell. one form of gene augmentiation is gene replacement therapy, a treatment for monogenic recessive disorders where a single gene is not functional an additional functional gene is added. for diseases caused by multiple genes or a dominant gene gene silencing or gene editing approaches are more appropriate but gene addition, a form of gene augmentation where new gene is added, may improve a cells function without modifying the genes that cause a disorder.: 117 cell types gene therapy may be classified into two types by the type of cell it affects: somatic cell and germline gene therapy. in somatic cell gene therapy (scgt), the therapeutic genes are transferred into any cell other than a gamete, germ cell, gametocyte, or undifferentiated stem cell. any such modifications affect the individual patient only, and are not inherited by offspring. somatic gene therapy represents mainstream basic and clinical research, in which therapeutic dna (either integrated in the genome or as an external episome or plasmid) is used to treat disease. over 600 clinical trials utilizing scgt are underway in the us. most focus on severe genetic disorders, including immunodeficiencies, haemophilia, thalassaemia, and cystic fibrosis. such single gene disorders are good candidates for somatic cell therapy. the complete correction of a genetic disorder or the replacement of multiple genes is not yet possible. only a few of the trials are in the advanced stages. in germline gene therapy (ggt), germ cells (sperm or egg cells) are modified by the introduction of functional genes into their genomes. modifying a germ cell causes all the organism's cells to contain the modified gene. the change is therefore heritable and passed on to later generations. australia, canada, germany, israel, switzerland, and the netherlands prohibit ggt for application in human beings, for technical and ethical reasons, including insufficient knowledge about possible risks to future generations and higher risks versus scgt. the us has no federal controls specifically addressing human genetic modification (beyond fda regulations for therapies in general). in vivo versus ex vivo therapies in in vivo gene therapy, a vector (typically, a virus) is introduced to the patient, which then achieves the desired biological effect by passing the genetic material (e.g. for a missing protein) into the patient's cells. in ex vivo gene therapies, such as car-t therapeutics, the patient's own cells (autologous) or healthy donor cells (allogeneic) are modified outside the body (hence, ex vivo) using a vector to express a particular protein, such as a chimeric antigen receptor. in vivo gene therapy is seen as simpler, since it does not require the harvesting of mitotic cells. however, ex vivo gene therapies are better tolerated and less associated with severe immune responses. the death of jesse gelsinger in a trial of an adenovirus-vectored treatment for ornithine transcarbamylase deficiency due to a systemic inflammatory reaction led to a temporary halt on gene therapy trials across the united states. as of 2021, in vivo and ex vivo therapeutics are both seen as safe. gene editing